11 results on '"Felipe de Arriba de la Fuente"'
Search Results
2. How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
- Author
-
Felipe de Arriba de la Fuente, Carmen Montes Gaisán, and Javier de la Rubia Comos
- Subjects
multiple myeloma ,lenalidomide ,relapse ,refractory ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Although lenalidomide-based combinations, such as lenalidomide plus a proteasome inhibitor or an anti-CD38 monoclonal antibody, improve the overall response rate, progression-free survival, and overall survival of patients with relapsed/refractory multiple myeloma (RRMM), there is a tendency to use these regimens as a frontline treatment. This strategy has led to the development of refractoriness early in the disease course, usually after the patient’s first treatment. Since lenalidomide-free regimens have so far shown limited efficacy in lenalidomide-refractory patients, there is an unmet need for other treatment options. In this review, we discuss the therapeutic options available to treat the general population of lenalidomide-refractory patients (mono, double and triple refractory) and the subpopulation of patients with other high-risk features such as renal failure, extramedullary disease, and high-risk cytogenetics. Moreover, new promising individual therapies and the possible impact of immunotherapy in RRMM patients are debated.
- Published
- 2022
- Full Text
- View/download PDF
3. P-090: Immune biomarkers of survival and infectionrelated mortality in multiple myeloma (MM) patients treated with lenalidomide and dexamethasone (Rd)
- Author
-
Catarina Maia, Noemí Puig, Maria-Teresa Cedena, Norma Gutiérrez, María-J Calassanz, Maria-L Martín-Ramos, Miguel Teodoro Hernandez Garcia, Laura Rosiñol, Mª Esther González, Felipe de Arriba de la Fuente, Albert Oriol, Verónica González, Fernando Escalante, Javier De la Rubia, Mercedes Gironella Mesa, Rafael Ríos, Ricarda García-Sánchez, José-M Arguiñano, Adrián Alegre, Jesus San-Miguel, Juan José Lahuerta Palacios, Joan Blade, Ruben Niesvizky, María-Victoria Mateos, and Bruno Paiva
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
4. P-197: A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: carinae study
- Author
-
Felipe de Arriba de la Fuente, Miguel Teodoro Hernandez Garcia, Juan Alfons Soler Campos, Susana Herráez Rodriguez, Mª José Moreno, Miriam Conzález Pardo, Mercedes Gironella Mesa, and María Casanova Espinosa
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
5. OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial
- Author
-
Juan José Lahuerta Palacios, Ana Jiménez Ubieto, Laura Rosiñol, Bruno Paiva, Joaquín Martinez López, María Teresa Cedena, Noemí Puig, Rafael Ríos, Albert Oriol, María Jesús Blanchard, Joan Bargay, Jesús Martín, Rafael martinez, Anna Sureda, Javier De la Rubia, Miguel teodoro Hernández, Valentín Cabañas, Isabel krsnik, Luis Palomera, Felipe Casado, Yolanda Gonzalez-Montes, Felipe de Arriba de la Fuente, María-Victoria Mateos, Jesus San-Miguel, and Joan Blade
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
6. OAB-050: Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple (MM) patients (GEMKyCyDex)
- Author
-
Borja Puertas, Verónica González, Anna Sureda, Mª José Moreno, Albert Oriol, Mª Esther González, Laura Rosiñol, Jordi López, Fernando Escalante, Joaquín Martinez López, Estrella Carrillo, Esther Clavero, Ana Pilar González Rodríguez, Victoria Dourdil, Felipe de Arriba de la Fuente, Marta Sonia González, Jaime Pérez de Oteyza, Miguel teodoro Hernández, Aránzazu García Mateo, Joan Blade, Juan José Lahuerta Palacios, Jesus San-Miguel, Enrique Ocio, and María-Victoria Mateos
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
7. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
- Author
-
Meral Beksac, Zhaoyang Teng, S. Vincent Rajkumar, Martin Kaiser, Philippe Moreau, María-Victoria Mateos, Felipe de Arriba de la Fuente, Fredrik Schjesvold, Sharon West, Andrew Spencer, Richard Labotka, Michael Czorniak, Cong Li, Roman Hájek, Nina Gulbrandsen, Meletios A. Dimopoulos, and Kaveri Suryanarayan
- Subjects
medicine.medical_specialty ,Nausea ,business.industry ,Context (language use) ,Hematology ,General Medicine ,medicine.disease ,Placebo ,Ixazomib ,Discontinuation ,chemistry.chemical_compound ,chemistry ,Multiple myeloma ,Internal medicine ,Adverse events ,medicine ,Vomiting ,Original Article ,medicine.symptom ,Maintenance therapy ,Safety ,Adverse effect ,business ,Progressive disease - Abstract
The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in multiple myeloma patients. We report additional safety data from TOURMALINE-MM3 to inform adverse event (AE) management recommendations. Patients were randomized 3:2 to receive ixazomib (n = 395) or placebo (n = 261) on days 1, 8, and 15 of 28-day cycles for ~ 2 years or until progressive disease/toxicity. The initial 3-mg ixazomib dose was escalated to 4 mg in cycle 5, if tolerated in cycles 1–4. Safety was a secondary endpoint assessed in all treated patients; AEs were graded using Common Terminology Criteria for AEs v4.03. The rate of grade ≥ 3 AEs was higher in the ixazomib arm (19%) than in the placebo arm (5%), but the rate of discontinuation due to AEs was similar (7% vs. 5%). For AEs of clinical interest, rates were higher with ixazomib versus placebo: nausea 39% versus 15%, vomiting 27% versus 11%, diarrhea 35% versus 24%, thrombocytopenia 13% versus 3%, and peripheral neuropathy 19% versus 15%. However, the majority of events were low-grade, manageable with supportive therapy or dose reduction, and reversible, and did not result in discontinuation. There was no evidence of cumulative, long-term, or late-onset toxicity with ixazomib maintenance. Ixazomib is an efficacious and tolerable option for post-ASCT maintenance. AEs associated with ixazomib maintenance can be managed in the context of routine post-ASCT supportive care due to the limited additional toxicity. ClinicalTrials.gov NCT02181413
- Published
- 2020
8. Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
- Author
-
Richard Labotka, Meletios A. Dimopoulos, Cong Li, Sharon West, Nina Gulbrandsen, Zhaoyang Teng, Martin Kaiser, Kaveri Suryanarayan, Andrew Spencer, S. Vincent Rajkumar, Meral Beksac, Michael Czorniak, Fredrik Schjesvold, Felipe de Arriba de la Fuente, María-Victoria Mateos, Roman Hájek, and Philippe Moreau
- Subjects
Oncology ,Boron Compounds ,Male ,medicine.medical_specialty ,MEDLINE ,Glycine ,Disease-Free Survival ,Ixazomib ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Adverse effect ,Autografts ,Multiple myeloma ,Aged ,Hematology ,business.industry ,Silicates ,Correction ,General Medicine ,Middle Aged ,medicine.disease ,Post transplant ,Survival Rate ,chemistry ,Female ,business ,Multiple Myeloma ,Follow-Up Studies ,Stem Cell Transplantation - Abstract
The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in multiple myeloma patients. We report additional safety data from TOURMALINE-MM3 to inform adverse event (AE) management recommendations. Patients were randomized 3:2 to receive ixazomib (n = 395) or placebo (n = 261) on days 1, 8, and 15 of 28-day cycles for ~ 2 years or until progressive disease/toxicity. The initial 3-mg ixazomib dose was escalated to 4 mg in cycle 5, if tolerated in cycles 1-4. Safety was a secondary endpoint assessed in all treated patients; AEs were graded using Common Terminology Criteria for AEs v4.03. The rate of grade ≥ 3 AEs was higher in the ixazomib arm (19%) than in the placebo arm (5%), but the rate of discontinuation due to AEs was similar (7% vs. 5%). For AEs of clinical interest, rates were higher with ixazomib versus placebo: nausea 39% versus 15%, vomiting 27% versus 11%, diarrhea 35% versus 24%, thrombocytopenia 13% versus 3%, and peripheral neuropathy 19% versus 15%. However, the majority of events were low-grade, manageable with supportive therapy or dose reduction, and reversible, and did not result in discontinuation. There was no evidence of cumulative, long-term, or late-onset toxicity with ixazomib maintenance. Ixazomib is an efficacious and tolerable option for post-ASCT maintenance. AEs associated with ixazomib maintenance can be managed in the context of routine post-ASCT supportive care due to the limited additional toxicity. ClinicalTrials.gov NCT02181413.
- Published
- 2020
9. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
- Author
-
Meletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, Meral Beksac, Roman Hajek, Katja Christina Weisel, Hartmut Goldschmidt, Vladimir Maisnar, Philippe Moreau, Chang Ki Min, Agnieszka Pluta, Wee-Joo Chng, Martin Kaiser, Sonja Zweegman, Maria-Victoria Mateos, Andrew Spencer, Shinsuke Iida, Gareth Morgan, Kaveri Suryanarayan, Zhaoyang Teng, Tomas Skacel, Antonio Palumbo, Ajeeta B Dash, Neeraj Gupta, Richard Labotka, S Vincent Rajkumar, Daniel Bar, Alfredo Basso, Dorotea Fantl, Simon He, Neomi Horvath, Cindy Lee, Phillip Rowlings, Kerry Taylor, Tara Cochrane, Fiona Kwok, Sundreswran Ramanathan, Hermine Agis, Niklas Zojer, Alain Kentos, Fritz Offner, Jan Van Droogenbroeck, Ka Lung Wu, Angelo Maiolino, Gracia Martinez, Karla Zanella, Marcelo Capra, Sérgio Araújo, Evzen Gregora, Ludek Pour, Vlastimil Scudla, Ivan Spicka, Niels Abildgaard, Niels Andersen, Bo Amdi Jensen, Carsten Helleberg, Torben Plesner, Morten Salomo, Asta Svirskaite, Richard Delarue, Igor Blau, Aneta Schieferdecker, Veronica Teleanu, Markus Munder, Christoph Röllig, Han-Juergen Salwender, Stephan Fuhrmann, Katja Weisel, Jan Duerig, Matthias Zeis, Stefan Klein, Peter Reimer, Christian Schmidt, Christof Scheid, Karin Mayer, Martin Hoffmann, Markus Sosada, Athanasios Dimopoulos, Sosana Delimpasi, Mary-Christine Kyrtsonis, Achilleas Anagnostopoulos, Zsolt Nagy, Árpád Illés, Miklós Egyed, Zita Borbényi, Gabor Mikala, Najib Dally, Netanel Horowitz, Odit Gutwein, Anatoly Nemets, Iuliana Vaxman, Olga Shvetz, Svetlana Trestman, Rosa Ruchlemer, Arnon Nagler, Tamar Tadmor, Ory Rouvio, Meir Preis, Michele Cavo, Luca De Rosa, Pellegrino Musto, Anna Cafro, Patrizia Tosi, Massimo Offidani, Alessandro Corso, Giuseppe Rossi, Anna Marina Liberati, Alberto Bosi, Kenshi Suzuki, Chiaki Nakaseko, Takayuki Ishikawa, Morio Matsumoto, Hirokazu Nagai, Kazutaka Sunami, Takaaki Chou, Koichi Akashi, Naoki Takezako, Shotaro Hagiwara, Hyeon Seok Eom, Deog-Yeon Jo, Jin Seok Kim, Jae Hoon Lee, Sung Soo Yoon, Dok Hyun Yoon, Kihyun Kim, Mark-David Levin, Edo Vellenga, Monique Minnema, Anders Waage, Einar Haukås, Sebastian Grosicki, Andrzej Pluta, Tadeusz Robak, Herlander Marques, Rui Bergantim, Fernando Campilho, Wee Joo Chng, Yeow Tee Goh, Andrew McDonald, Bernado Rapoport, Miguel Angel Álvarez Rivas, Felipe De Arriba de La Fuente, Yolanda González Montes, Jesus Martin Sanchez, Maria Victoria Mateos, Albert Oriol Rocafiguera, Laura Rosinol, Jesús San Miguel, Jaime Pérez de Oteyza, Cristina Encinas, Adrian Alegre-Amor, Ana López-Guía, Per Axelsson, Kristina Carlson, Olga Stromberg, Markus Hansson, Cecile Hveding Blimark, Rouven Mueller, Chih-Cheng Chen, Ta-Chih Liu, Shang-Yi Huang, Po-Nan Wang, Thanyaphong Na Nakorn, Kannadit Prayongratana, Ali Unal, Hakan Goker, Mehmet Sonmez, Sybiryna Korenkova, Aristeidis Chaidos, Heather Oakervee, Hamdi Sati, Reuben Benjamin, Ashutosh Wechalekar, Mamta Garg, Karthik Ramasamy, Gordon Cook, Andrew Chantry, Matthew Jenner, Francis Buadi, Robert Berryman, Murali Janakiram, Takeda Pharmaceutical Company, Dimopoulos MA1, Gay F2, Schjesvold F3, Beksac M4, Hajek R5, Weisel KC6, Goldschmidt H7, Maisnar V8, Moreau P9, Min CK10, Pluta A11, Chng WJ12, Kaiser M13, Zweegman S14, Mateos MV15, Spencer A16, Iida S17, Morgan G18, Suryanarayan K19, Teng Z19, Skacel T19, Palumbo A20, Dash AB19, Gupta N19, Labotka R19, Rajkumar SV21, TOURMALINE-MM3 study group. Bar D, Basso A, Fantl D, He S, Horvath N, Lee C, Rowlings P, Taylor K, Spencer A, Cochrane T, Kwok F, Ramanathan S, Agis H, Zojer N, Kentos A, Offner F, Van Droogenbroeck J, Wu KL, Maiolino A, Martinez G, Zanella K, Capra M, Araújo S, Gregora E, Hajek R, Maisnar V, Pour L, Scudla V, Spicka I, Abildgaard N, Andersen N, Jensen BA, Helleberg C, Plesner T, Salomo M, Svirskaite A, Delarue R, Moreau P, Blau I, Goldschmidt H, Schieferdecker A, Teleanu V, Munder M, Röllig C, Salwender HJ, Fuhrmann S, Weisel K, Duerig J, Zeis M, Klein S, Reimer P, Schmidt C, Scheid C, Mayer K, Hoffmann M, Sosada M, Dimopoulos A, Delimpasi S, Kyrtsonis MC, Anagnostopoulos A, Nagy Z, Illés Á, Egyed M, Borbényi Z, Mikala G, Dally N, Horowitz N, Gutwein O, Nemets A, Vaxman I, Shvetz O, Trestman S, Ruchlemer R, Nagler A, Tadmor T, Rouvio O, Preis M, Gay F, Cavo M, De Rosa L, Musto P, Cafro A, Tosi P, Offidani M, Corso A, Rossi G, Liberati AM, Bosi A, Suzuki K, Iida S, Nakaseko C, Ishikawa T, Matsumoto M, Nagai H, Sunami K, Chou T, Akashi K, Takezako N, Hagiwara S, Eom HS, Jo DY, Kim JS, Lee JH, Min CK, Yoon SS, Yoon DH, Kim K, Zweegman S, Levin MD, Vellenga E, Minnema M, Schjesvold F, Waage A, Haukås E, Grosicki S, Pluta A, Robak T, Marques H, Bergantim R, Campilho F, Chng WJ, Goh YT, McDonald A, Rapoport B, Álvarez Rivas MA, De Arriba de La Fuente F, González Montes Y, Martin Sanchez J, Mateos MV, Oriol Rocafiguera A, Rosinol L, San Miguel J, Pérez de Oteyza J, Encinas C, Alegre-Amor A, López-Guía A, Axelsson P, Carlson K, Stromberg O, Hansson M, Hveding Blimark C, Mueller R, Chen CC, Liu TC, Huang SY, Wang PN, Na Nakorn T, Prayongratana K, Beksac M, Unal A, Goker H, Sonmez M, Korenkova S, Chaidos A, Oakervee H, Sati H, Benjamin R, Wechalekar A, Garg M, Kaiser M, Ramasamy K, Cook G, Chantry A, Jenner M, Buadi F, Berryman R, Janakiram M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, CCA - Cancer biology and immunology, and Hematology
- Subjects
Male ,Time Factors ,DIAGNOSED MULTIPLE-MYELOMA ,Clinical Trial, Phase III ,Administration, Oral ,030204 cardiovascular system & hematology ,Ixazomib ,chemistry.chemical_compound ,0302 clinical medicine ,Autologous stem-cell transplantation ,Maintenance therapy ,Clinical endpoint ,030212 general & internal medicine ,Non-U.S. Gov't ,Boron Compounds/administration & dosage ,IMPROVES SURVIVAL ,INDUCTION ,Research Support, Non-U.S. Gov't ,General Medicine ,CHEMOTHERAPY ,Middle Aged ,Clinical Trial ,DEXAMETHASONE ,Antineoplastic Agents/administration & dosage ,Multicenter Study ,Treatment Outcome ,Administration ,Randomized Controlled Trial ,Disease Progression ,Female ,Multiple Myeloma ,Autologous ,Boron Compounds ,Oral ,medicine.medical_specialty ,Glycine ,Multiple Myeloma/drug therapy ,BORTEZOMIB ,Antineoplastic Agents ,Placebo ,Research Support ,Transplantation, Autologous ,03 medical and health sciences ,Phase III ,Double-Blind Method ,Internal medicine ,medicine ,Journal Article ,Humans ,THALIDOMIDE ,Transplantation ,business.industry ,Clinical trial ,LENALIDOMIDE MAINTENANCE ,Regimen ,chemistry ,autologous stem cell transplantation, multiple myeloma, Ixazomib ,business ,HIGH-DOSE THERAPY ,Glycine/administration & dosage ,Stem Cell Transplantation - Abstract
[Background]: Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. [Methods]: The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m²) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1–4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. [Findings]: Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3–35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7–33·8] vs 21·3 months [18·0–24·7]; hazard ratio 0·72, 95% CI 0·58–0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. [Interpretation]: Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma, This study was sponsored by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.
- Published
- 2019
10. Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
- Author
-
Maria Soledad Duran, Miriam González-Pardo, Felipe de Arriba de la Fuente, Aurelia Tejedor, Elena Prieto, Maria Victoria Mateos Manteca, Miguel Ángel Álvarez, Carmen Couto, Abelardo Bárez, Isabel López Sanromán, Francisco Javier Capote, Marta González, Fernando Escalante, Mónica Ballesteros, Rafael Ríos Tamayo, Ana Maria Dios, R. García, Sebastián Garzón, and Valentin Cabañas
- Subjects
Male ,medicine.medical_specialty ,Anemia ,Injections, Subcutaneous ,Antineoplastic Agents ,Neutropenia ,Bortezomib ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Adverse effect ,Multiple myeloma ,Aged ,Retrospective Studies ,Very Good Partial Response ,Aged, 80 and over ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Surgery ,Peripheral neuropathy ,Treatment Outcome ,Tolerability ,030220 oncology & carcinogenesis ,Female ,business ,Multiple Myeloma ,030215 immunology ,medicine.drug - Abstract
Bortezomib-melphalan-prednisone combination is one of the standards of care for nontransplant eligible patients with newly diagnosed multiple myeloma. However, bortezomib intravenous (twice weekly for 4 cycles then weekly for 5 cycles) results in ~13% of patients with grade 3-4 peripheral neuropathy. Bortezomib subcutaneous (SQ) and weekly delivery, improves tolerability without impairment of efficacy. The aim of this study was to evaluate the safety and effectiveness of SQ bortezomib-based combinations in nontransplant eligible patients with newly diagnosed myeloma in a real-world setting. A total of 135 patients (median age [range] = 76 [58-89], International Staging System-III = 54%, median follow-up = 14.8 months [1-40], Intensive group [twice weekly bortezomib] = 65%, Optimized group [weekly bortezomib] = 35%) were included and evaluable for safety, whereas 121 were evaluable for effectiveness. Overall response rate (95% CI) was 61% (53%, 71%) (complete response = 27%, very good partial response = 13%, and partial response = 21%) and median progression-free survival was 22.2 months (95% CI: 16.1-not reached). The 3-year overall survival was 75%. The most frequent grade 3-4 adverse events were thrombocytopenia (18%), neutropenia (17%), and anemia (11%). Peripheral neuropathy of any grade was observed in 44% of patients (2% with grade 3). Comparison between regimens (Intensive vs Optimized) showed similar overall response rate (57% vs 70%) and PFS (25 vs 19 months). A similar safety profile was observed between regimens. Thus, SQ bortezomib showed similar effectiveness and better tolerability as compared with results from intravenous bortezomib studies, and showing no differences either in effectiveness or safety in different bortezomib-based combinations.
- Published
- 2017
11. Cambra system in patients awaiting hematopoietic progenitor cell transplant and high caries risk
- Author
-
Felipe De Arriba-de la Fuente, Ricardo-Elias Oñate-Sánchez, Vicente Vicente-García, Pastora Iniesta-López-Matencio, Ana Hernández-Fernández, and Antonio-José Ortiz-Ruiz
- Subjects
medicine.medical_specialty ,business.industry ,Research ,Dentistry ,030206 dentistry ,Disease ,Oral health ,CIENCIAS MÉDICAS [UNESCO] ,Conservative treatment ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Hematopoietic progenitor ,Carious teeth ,030220 oncology & carcinogenesis ,Internal medicine ,Radiological weapon ,UNESCO::CIENCIAS MÉDICAS ,medicine ,In patient ,Odontostomatology for the Disabled or Special Patients ,business ,General Dentistry - Abstract
Background Recent times have witnessed a significant increase in the number of patients affected by problems related to oncological treatment Aims of this study is to evaluate dental affectation among patients awaiting hematopoietic progenitor cell transplant (HPCT), and they showed high caries risk, so it should establish a protocol prior to transplantation. Material and methods The study included 72 patients due for HPCT. Clinical and radiological explorations were performed and oral photos taken. The amount of caries, missing teeth and fillings were registered for each patient. CAO, DMFS and Restoration Indices were calculated. Results 83% of patients presented caries. 48 patients (67%) had lost at least one tooth. Only 32 patients (44%) had received some sort of conservative treatment. The average CAO index value obtained was 10.37. The DMFS index showed an average of 27.06 affected surfaces. Of the 72 patients studied, 40 (56%) showed a restoration index value of zero. Conclusions These patients presented a high number of carious teeth and a low restoration index. The presence of so many possible septic foci in an individual, who will later become susceptible to infection, highlights the importance of preventative treatment and bucco-dental restoration within this patient population. These patients with a high caries risk can be treated with CAMBRA system. Key words:Hematopoietic progenitor cell transplantation, high caries risk, state of oral health, haematological disease, CAMBRA system.
- Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.